My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$EBAY {{ '2015-10-21T21:42:20+0000' | timeago}} • Webcast

$EBAY said its cost of revenue grew 160 basis points YoverY, driven by the impact of foreign exchange and the payment processing cost, which now include the effects of the agreements with PayPal. Operating expenses were 48.1% of revenue in 3Q15, down 67 basis points versus last year.

User Vishnu Beri {{ '2016-10-25T21:15:45+0000' | timeago}}

Apple ($AAPL) reported decline in sales and profits from comparable quarter last year, attributing the decline to announcement of iPhone 7/7s. Sales and profit are being guided higher for next quarter. Apple is a solid company and will continue to dominate tech and consumer electronics segment for a while. Personally, looks like there is little downside in this investment.

User Mark Collas {{ '2016-10-25T20:12:01+0000' | timeago}}

Waiting with fingers crossed for $AAPL’s fourth quarter earnings.

User RC xNair {{ '2016-10-25T17:04:47+0000' | timeago}}

Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."

User Carlton Davis {{ '2016-10-24T19:31:20+0000' | timeago}}

$COL agreed to buy $BEAV for $6.4 billion in cash and stock. Also Rockwell Collins reported higher 4Q16 earnings on growth in Government Systems and higher revenue in Information Management Services.

User Charles Elliston {{ '2016-10-24T19:15:21+0000' | timeago}}

Wow! What a buzz the $T-$TWX deal is making! Almost everyone from politicians to competitors have come out against this deal. Even Wall Street doesn’t seem to be too thrilled. Both stocks were down today.

$BIIB {{ '2016-10-26T13:23:22+0000' | timeago}} • Webcast

$BIIB's collaboration partner Eisai has stated their goal to start a Phase III trial for E2609. A $50MM milestone payment is expected to be triggered once the first patient is dosed in the trial. There is a potential chance they could dose the first patient by the end of 2016. The $50MM milestone was not considered in the mid-year 2016 R&D outlook.

$CMCSA {{ '2016-10-26T13:23:02+0000' | timeago}} • Webcast

In the advanced advertising area, $CMCSA has a full rollout of VOD dynamic ad insertion, which is becoming more effective. The company is testing linear addressable advertising in a number of markets which is working. $CMCSA is making progress in leveraging acquisitions and existing advertising capabilities and believes this is a growth business.

$KO {{ '2016-10-26T13:21:34+0000' | timeago}} • Webcast

$KO's core business performed well with a 4% organic revenue growth YTD, in line with the company's long term target. Additionally, within the core business, developed markets performed well, with a YTD unit case volume growth of 2%.

$MDLZ {{ '2016-10-26T13:21:06+0000' | timeago}} • Announcement

Food and confectionery giant $MDLZ reported a 3Q16 profit of $0.35, down 92% due to prior year's $7Bil gain related to the company's coffee business transactions. Net revenues decreased 6.6% to $6.4Bil.

$BIIB {{ '2016-10-26T13:15:56+0000' | timeago}} • Webcast

$BIIB's Tysabri worldwide revenue was $515MM in 3Q16, an increase of 7% versus last year. This included $301MM in the US and $214MM outside the US. Tysabri revenue outside the US benefited by $20MM, due to a favorable adjustment to the company's discounts in allowances. ForEx and the hedge impact weakened Tysabri sales by approx. $16MM versus 3Q15.